KEYNOTE-671, KEYTRUDA, Merck Poland, NSCLC, Pembrolizumab
Neoadjuvant/ adjuvant pembrolizumab FDA approbatur pro resectabili cancro cellulae non-miniculo
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
Ordinare BioPharma Inc, binmetinib, Braftovi, encorafenib, Mektovi, laboratorium Pfizer
Encorafenib cum binimetinib approbatur a FDA ad tractationem cancri metastatici non-miniculi cellulae pulmonis cum BRAF V600E mutatione.
Cibus et medicamentum Administrationis (FDA) approbavit Encorafenib (Braftovi, Array BioPharma Inc., subsidiaria totius Pfizer) et binimetinib (Mektovi, Array BioPharma Inc.) mense Novembri 2023 ut medicamenta quae adhiberi possunt ad t.
SAGITTA iudicium, Genentech, NSCLC, pralsetinib
Pralsetinib approbatur a FDA pro cancro cellulae non parvae cum fusions gene ret
Augusti 2023: Pralsetinib (Gavreto, Genentech, Inc.) approbatio ordinaria data est a Administration Cibus et medicamentis ad aegros adultos cum metastatica RET fusione-positiva non parva cellula pulmonis cancri (NSCLC), secundum determinatum FDA.
FDA, Cibus et medicamentis Administration, KEYTRUDA, Merck Poland, Pembrolizumab, platinum-fundatur chemotherapy
Pembrolizumab approbatur a FDA ad adjuvandum curationem carcinomatis cellulae non parvae
Feb 2023: Pro scaena IB (T2a 4 cm), scaena II, sive scaena IIIA pulmonis cellae non parvae, Cibus et medicamentum Administration (FDA) approbatum pembrolizumab (Keytruda, Merck) adiuvantibus therapiis post resectionem et chemoth platinum substructum. .
AstraZeneca Pharmaceuticals, durvalumab, Imjudo, NSCLC, POSEIDON, tremelimumab
Tremelimumab FDA approbatur in compositione cum durvalumab et platino substructio chemotherapy pro metastatica cellulae pulmonis non parvae
Novembris 2022: Compositio tremelimumab (Imjudo, AstraZeneca pharmaceutica), durvalumab (Imfinzi, AstraZeneca pharmaceutica), et platinum-substructio chemotherapy probatum est ab Administratione Cibus et medicamentis adulti pa.
Libtayo, NCT03409614, NSCLC, platinum-fundatur chemotherap, Regeneron Pharma
Cemiplimab-rwlc approbatur a FDA in compositione cum chemotherapia substructa pro cancro non parvo cellula pulmonis.
November 2022: Compositio cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) et platinum-substructio chemotherapy pro adultis aegris cum non-magna cellula pulmonis cancri progresso (NSCLC) sine EGFR, ALK, vel ROS1 abnormal.
am-trastuzumab deruxtecan-nxki, Daiichi Sankyo, Enhertu
Accelerata approbatio a FDA ad fam trastuzumab deruxtecan-nxki conceditur pro HER2-mutante non-magna pulmonis cellae cancri.
Augusti 2022: Pro adultis aegris cum metastatica cellulae non-parvae pulmonis cancri (NSCLC) quorum tumores mutationem habent consequens transitus mesenchymal-epithelialis (MET) exon 14 gestientes, ut detecti per experimentum FDA probati, Cibus.
Capmatinib, NCT02414139, Novartis Pharmaceuticals Corp, NSCLC, Tabrecta
Capmatinib approbatur pro metastatico cellae pulmonis non parvae
Augusti 2022: Pro adultis aegris cum metastatica cellulae non-parvae pulmonis cancri (NSCLC) quorum tumores mutationem habent consequens transitus mesenchymal-epithelialis (MET) exon 14 gestientes, ut detecti per experimentum FDA probati, Cibus.
BMS, CHECKMATE DCXLIX,, niveumab, NSCLC, Mirabilis
Neoadjuvante nivolumab et platinum-duplicatum chemotherapy probatum est pro praematuro cancro cellulae non-parvae pulmonis.
Martii 2022: In neoadjuvante occasu, FDA approbavit nivolumab (Opdivo, Societas Bristol-Myers Squibb) in compositione cum chemothera platino-duplicata pro adultis aegris cum resectabili non-parva cellula pulmonis cancri (NSCLC).Thi.
Atezolizumab, Genentech, NSCLC, Tecentriq, Ventana Systems Medicum, VENTANA PD-L1
Atezolizumab approbatur a FDA ad adjuvandum curationem carcinomatis cellulae non parvae
Nov 2021: Cibus et medicamentum Administrationis atezolizumab (Tecentriq, Genentech, Inc.) approbavit curationem patientibus scaena II ad IIIA non parvam cellulam pulmonis cancri (NSCLC) cuius tumores expressio PD-L1 continent o.